Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.

Jianli Zhou¹, Daruka Mahadevan², Jay Parekh², Marc Chamberlain¹, Kishor Bhatia¹, Reginald Ewesuedo³

¹Lantern Pharma Inc., Plano, TX, 75024, USA.

²Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.

³Lantern Pharma Inc., Plano, TX, 75024, USA. rewesuedo@lanternpharma.com.

PubMed DOI

Abstract

PURPOSE: Safety evaluation in first-in-human (FIH) Phase 1 oncology trials is largely descriptive and provides limited quantitative insights. This study characterized the dynamics of platelet count (PLT) and alanine aminotransferase (ALT) concentration in the LP-184 FIH study and explored statistical modeling to support personalized dosing strategies. METHODS: PLT and ALT data were analyzed to ch…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.